PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer

Clinical trial NCT07472140 · RECRUITING

Trial details

NCT number: NCT07472140
Sponsor: N.N. Alexandrov National Cancer Centre
Status: RECRUITING
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

Ovarian Cancer Fallopian Tube Cancers Primary Peritoneal Cancer

Start date: 2025-07-01
Primary completion: 2033-06-30
Enrollment: 120

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.